Targeting intracellular pathways in idiopathic inflammatory myopathies: A narrative review

Gaetano La Rocca; Francesco Ferro; Chiara Baldini; Alessandro Libra; Domenico Sambataro; Michele Colaci; Lorenzo Malatino; Stefano Palmucci; Carlo Vancheri; Gianluca Sambataro

doi:10.3389/fmed.2023.1158768

Targeting intracellular pathways in idiopathic inflammatory myopathies: A narrative review

Front Med (Lausanne). 2023 Mar 13:10:1158768. doi: 10.3389/fmed.2023.1158768. eCollection 2023.

Authors

Affiliations

¹ Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
² Regional Referral Centre for Rare Lung Disease, Azienda Ospedaliero Universitaria Policlinico "G. Rodolico-San Marco", University of Catania, Catania, Italy.
³ Artroreuma S.R.L., Rheumatology Outpatient Clinic, Catania, Italy.
⁴ Internal Medicine Unit, Rheumatology Clinic, Azienda Ospedaliera per l'Emergenza Cannizzaro, University of Catania, Catania, Italy.
⁵ Department of Medical Surgical Sciences and Advanced Technologies "GF Ingrassia", University Hospital Policlinico "G. Rodolico-San Marco", Catania, Italy.

Abstract

In recent decades, several pieces of evidence have drawn greater attention to the topic of innate immunity, in particular, interferon (IFN) and Interleukin 6 in the pathogenesis of idiopathic inflammatory myopathies (IIM). Both of these molecules transduce their signal through a receptor coupled with Janus kinases (JAK)/signal transducer and activator of transcription proteins (STAT). In this review, we discuss the role of the JAK/STAT pathway in IIM, evaluate a possible therapeutic role for JAK inhibitors in this group of diseases, focusing on those with the strongest IFN signature (dermatomyositis and antisynthetase syndrome).

Keywords: 2; 3; Baricitinib; JAK/STAT 1; Tofacitinib; antisynthetase syndrome; dermatomyositis.

Publication types

Review